ASA reduces risk of cancer
A meta-analysis published in The Lancet Oncology
has confirmed that long-term aspirin use reduces the risk of cancer. Specifically, the risk of colorectal (OR=0.62), esophageal, gastric, biliary, and breast cancer was reduced in patients who used ASA long-term. Moreover, the risk of distant metastases (OR=0.69), but not regiona spread, was reduced.